<p>Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <em>ALK</em> Gene Have Durable Responses to ALK Kinase Inhibitors</p>
Alexa B. Schrock(GlobalFoundries (United States)), Siraj M. Ali(UPMC Hillman Cancer Center), Kimberly McGregor(Foundation Medicine (United States)), Tarek Chidiac(Mark H. Zangmeister Cancer Center), Abdur R. Shakir(Sarah Bush Lincoln Health System), Russell W. Madison(Foundation Medicine (United States)), Mark R. Rosenzweig(Blueprint Medicines (United States)), Siao‐Yi Wang, Brian M. Alexander(Brigham and Women's Hospital), Vodur Suresh Reddy, Jonathan W. Riess(University of California Davis Medical Center), Ahmet Ersin Yassa(UC Davis Comprehensive Cancer Center), Vincent A. Miller(Universidad San Carlos), Jeffrey M. Venstrom(Foundation Medicine (United States)), Justin Allen(Foundation Medicine (United States)), Rachel Erlich(Broad Institute)
Cited by 3
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k